KAREN KINDLER: Open Payments
NPI 1326002205 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,356 in 86 payments from 11 companies in 2025. Trend: 2023 $1,496 · 2024 $2,068 · 2025 $2,356
Food & beverage: $2,356
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 15 | $536 |
| Ipsen Biopharmaceuticals, Inc | 12 | $482 |
| Gilead Sciences, Inc. | 17 | $397 |
| ABBVIE INC. | 13 | $243 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $201 |
| Novo Nordisk Inc | 5 | $194 |
| Mallinckrodt Hospital Products Inc. | 6 | $149 |
| Intercept Pharmaceuticals, Inc. | 5 | $83 |
| Mirum Pharmaceuticals, Inc. | 2 | $34 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
Products named: REZDIFFRA, IQIRVO, MAVYRET, XIFAXAN, Wegovy, TERLIVAZ, OCALIVA, Livmarli.
Industry payments across TX — which companies pay providers there.
